TY - JOUR
T1 - Amyloid precursor protein in platelets of patients with Alzheimer disease
T2 - Effect of acetylcholinesterase inhibitor treatment
AU - Borroni, B.
AU - Colciaghi, F.
AU - Pastorino, L.
AU - Pettenati, C.
AU - Cottini, E.
AU - Rozzini, L.
AU - Monastero, R.
AU - Lenzi, G. L.
AU - Cattabeni, F.
AU - Di Luca, M.
AU - Padovani, A.
PY - 2001
Y1 - 2001
N2 - Background: Amyloid precursor protein (APP) forms with apparent molecular weights of 130, 110, and 106 kd are present in human platelets. It has been demonstrated that Alzheimer disease (AD) is specifically associated with a decreased APP forms ratio in platelets. Objective: To investigate whether acetylcholinesterase (AChE) inhibitor treatment modifies the ratio of platelet APP forms in patients with AD. Patients and Methods: From a large sample of patients with probable AD, 30 with mild to moderate AD were selected. Each patient underwent a clinical evaluation including the Mini-Mental State Examination (MMSE) and platelet APP forms analysis at baseline and after 30 days. During this interval, 20 of 30 patients with AD were treated with donepezil hydrochloride (5 mg/d), a piperidine phosphate-based cholinesterase inhibitor. Platelets were subjected to Western blot analysis using monoclonal antibody (22C11). The ratio between the immunoreactivity of the higher-molecular-weight APP form (130 kd) and the lower forms (106 and 110 kd) was measured. Results: All patients taking donepezil completed the 30 days of treatment without adverse effects. The platelet APP forms ratio at baseline did not differ between the 2 AD groups (mean±SD optical density ratio: untreated AD, 0.47±0.12; treated AD, 0.38±0.18), whereas a significant difference was found at follow-up (mean±SD optical density ratio: untreated AD, 0.45±0.17; treated AD, 0.77±0.29; P
AB - Background: Amyloid precursor protein (APP) forms with apparent molecular weights of 130, 110, and 106 kd are present in human platelets. It has been demonstrated that Alzheimer disease (AD) is specifically associated with a decreased APP forms ratio in platelets. Objective: To investigate whether acetylcholinesterase (AChE) inhibitor treatment modifies the ratio of platelet APP forms in patients with AD. Patients and Methods: From a large sample of patients with probable AD, 30 with mild to moderate AD were selected. Each patient underwent a clinical evaluation including the Mini-Mental State Examination (MMSE) and platelet APP forms analysis at baseline and after 30 days. During this interval, 20 of 30 patients with AD were treated with donepezil hydrochloride (5 mg/d), a piperidine phosphate-based cholinesterase inhibitor. Platelets were subjected to Western blot analysis using monoclonal antibody (22C11). The ratio between the immunoreactivity of the higher-molecular-weight APP form (130 kd) and the lower forms (106 and 110 kd) was measured. Results: All patients taking donepezil completed the 30 days of treatment without adverse effects. The platelet APP forms ratio at baseline did not differ between the 2 AD groups (mean±SD optical density ratio: untreated AD, 0.47±0.12; treated AD, 0.38±0.18), whereas a significant difference was found at follow-up (mean±SD optical density ratio: untreated AD, 0.45±0.17; treated AD, 0.77±0.29; P
UR - http://www.scopus.com/inward/record.url?scp=0035107233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035107233&partnerID=8YFLogxK
M3 - Article
C2 - 11255448
AN - SCOPUS:0035107233
VL - 58
SP - 442
EP - 446
JO - Archives of Neurology
JF - Archives of Neurology
SN - 0003-9942
IS - 3
ER -